Ironwood Pharmaceuticals Inc (IRWD) - Total Assets
Based on the latest financial reports, Ironwood Pharmaceuticals Inc (IRWD) holds total assets worth $285.13 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ironwood Pharmaceuticals Inc - Total Assets Trend (2007–2025)
This chart illustrates how Ironwood Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Ironwood Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
Ironwood Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Ironwood Pharmaceuticals Inc's total assets of $285.13 Million consist of 69.1% current assets and 30.9% non-current assets. Review IRWD total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 54.3% |
| Accounts Receivable | $46.74 Million | 11.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.04 Million | 0.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Ironwood Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Ironwood Pharmaceuticals Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ironwood Pharmaceuticals Inc's current assets represent 69.1% of total assets in 2025, a decrease from 87.7% in 2007.
- Cash Position: Cash and equivalents constituted 54.3% of total assets in 2025, up from 45.9% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 11.8% of total assets.
Ironwood Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Ironwood Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Ironwood Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.06 | 0.82 | 4.77 |
| Quick Ratio | 6.06 | 0.82 | 4.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $166.35 Million | $-40.77 Million | $549.68 Million |
Ironwood Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Ironwood Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.59 |
| Latest Market Cap to Assets Ratio | 1.69 |
| Asset Growth Rate (YoY) | 13.1% |
| Total Assets | $396.90 Million |
| Market Capitalization | $672.53 Million USD |
Valuation Analysis
Above Book Valuation: The market values Ironwood Pharmaceuticals Inc's assets above their book value (1.69x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Ironwood Pharmaceuticals Inc's assets grew by 13.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ironwood Pharmaceuticals Inc (2007–2025)
The table below shows the annual total assets of Ironwood Pharmaceuticals Inc from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $396.90 Million | +13.11% |
| 2024-12-31 | $350.91 Million | -25.51% |
| 2023-12-31 | $471.07 Million | -57.20% |
| 2022-12-31 | $1.10 Billion | -2.34% |
| 2021-12-31 | $1.13 Billion | +101.51% |
| 2020-12-31 | $559.24 Million | +38.86% |
| 2019-12-31 | $402.75 Million | +21.29% |
| 2018-12-31 | $332.05 Million | -45.18% |
| 2017-12-31 | $605.67 Million | -14.67% |
| 2016-12-31 | $709.82 Million | +14.65% |
| 2015-12-31 | $619.12 Million | +85.64% |
| 2014-12-31 | $333.51 Million | +19.55% |
| 2013-12-31 | $278.96 Million | +21.34% |
| 2012-12-31 | $229.91 Million | +10.02% |
| 2011-12-31 | $208.98 Million | -30.66% |
| 2010-12-31 | $301.37 Million | +85.51% |
| 2009-12-31 | $162.45 Million | +15.44% |
| 2008-12-31 | $140.72 Million | +3.54% |
| 2007-12-31 | $135.91 Million | -- |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well … Read more